Fiduciary Trust Co. boosted its holdings in shares of Zoetis Inc (NYSE:ZTS) by 15.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,546 shares of the company’s stock after buying an additional 2,227 shares during the quarter. Fiduciary Trust Co.’s holdings in Zoetis were worth $1,410,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the business. IFM Investors Pty Ltd raised its holdings in shares of Zoetis by 10.4% in the 1st quarter. IFM Investors Pty Ltd now owns 15,196 shares of the company’s stock valued at $1,269,000 after purchasing an additional 1,437 shares in the last quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp raised its holdings in shares of Zoetis by 55.4% in the 1st quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 119,000 shares of the company’s stock valued at $9,938,000 after purchasing an additional 42,400 shares in the last quarter. State of Tennessee Treasury Department raised its holdings in shares of Zoetis by 98.4% in the 1st quarter. State of Tennessee Treasury Department now owns 343,162 shares of the company’s stock valued at $28,657,000 after purchasing an additional 170,156 shares in the last quarter. Squar Milner Financial Services LLC acquired a new stake in shares of Zoetis in the 2nd quarter valued at $176,000. Finally, First Bank & Trust raised its holdings in shares of Zoetis by 8.8% in the 2nd quarter. First Bank & Trust now owns 12,992 shares of the company’s stock valued at $1,107,000 after purchasing an additional 1,055 shares in the last quarter. Institutional investors own 90.45% of the company’s stock.
In related news, insider Roxanne Lagano sold 2,000 shares of Zoetis stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $84.76, for a total transaction of $169,520.00. Following the sale, the insider now directly owns 22,023 shares in the company, valued at approximately $1,866,669.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kristin C. Peck sold 5,000 shares of Zoetis stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $86.22, for a total transaction of $431,100.00. The disclosure for this sale can be found here. Insiders have sold a total of 15,283 shares of company stock worth $1,366,924 over the last quarter. 0.35% of the stock is owned by company insiders.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 2nd. The company reported $0.77 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.06. Zoetis had a net margin of 19.95% and a return on equity of 72.30%. The firm had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.38 billion. During the same period last year, the business earned $0.53 EPS. Zoetis’s revenue for the quarter was up 11.5% compared to the same quarter last year. equities analysts expect that Zoetis Inc will post 3.08 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 4th. Investors of record on Friday, July 20th will be paid a dividend of $0.126 per share. The ex-dividend date of this dividend is Thursday, July 19th. This represents a $0.50 annualized dividend and a yield of 0.55%. Zoetis’s dividend payout ratio is currently 20.83%.
A number of brokerages have recently weighed in on ZTS. Stifel Nicolaus raised their price objective on shares of Zoetis from $86.00 to $95.00 and gave the company a “buy” rating in a report on Friday, August 3rd. Morgan Stanley raised their price objective on shares of Zoetis from $87.00 to $92.00 and gave the company a “hold” rating in a report on Friday, August 3rd. BMO Capital Markets restated a “hold” rating and issued a $82.00 price objective on shares of Zoetis in a report on Thursday, August 2nd. Cantor Fitzgerald set a $98.00 price objective on shares of Zoetis and gave the company a “buy” rating in a report on Thursday, August 2nd. Finally, Hilliard Lyons lowered shares of Zoetis to a “neutral” rating in a report on Thursday, April 19th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have assigned a buy rating to the stock. Zoetis presently has a consensus rating of “Buy” and a consensus target price of $89.64.
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
See Also: Diversification For Individual Investors
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.